Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Pennsylvania: - Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Chambersburg Hospital — Chambersburg, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
- Ephrata Cancer Center — Ephrata, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Pennsylvania: - Alliance Cancer Specialists, PC — Bensalem, Pennsylvania
- Consultants in Medical Oncology and Hematology, P.C. — Broomall, Pennsylvania
- Alliance Cancer Specialists, PC — Doylestown, Pennsylvania
- Alliance Cancer Specialists, PC — Horsham, Pennsylvania
- Alliance Cancer Specialists, P.C. — Langhorne, Pennsylvania
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Pennsylvania: - Research Site — Hershey, Pennsylvania
- Research Site — York, Pennsylvania
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Pennsylvania: - Geisinger Medical Center — Danville, Pennsylvania
- Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania
- Geisinger Medical Oncology-Lewisburg — Lewisburg, Pennsylvania
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion — Mechanicsburg, Pennsylvania
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in Pennsylvania: - St. Luke's University Health Network — Bethlehem, Pennsylvania
- Allegheny Cancer Center — Pittsburgh, Pennsylvania
- Reading Hospital - McGlinn Cancer Institute — West Reading, Pennsylvania
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Pennsylvania: - St. Lukes Hospital and Health Network ( Site 0186) — Bethlehem, Pennsylvania
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Pennsylvania: - Local Institution - 0688 — Easton, Pennsylvania
- Local Institution - 0376 — Hershey, Pennsylvania
- WellSpan Oncology Research — York, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Pennsylvania: - Lancaster General Hospital — Lancaster, Pennsylvania
- Local Institution - 0028 — Pittsburgh, Pennsylvania
- WellSpan Oncology Research — York, Pennsylvania
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Pennsylvania: - Thomas Jefferson University — Philadelphia, Pennsylvania
- Allegheny — Pittsburgh, Pennsylvania
- UPMC Health System — Pittsburgh, Pennsylvania
- Mount Nittany — State College, Pennsylvania
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Pennsylvania: - Research Site — Fountain Hill, Pennsylvania
- Research Site — Kittanning, Pennsylvania
- Research Site — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in Pennsylvania: - Consultants in Medical Oncology and Hematology — Broomall, Pennsylvania
- Alliance Cancer Specialists — Media, Pennsylvania
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- University of Pittsburgh (UPMC) Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT07365241
Sites in Pennsylvania: - St. Lukes University Hospital /ID# 280204 — Bethlehem, Pennsylvania
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in Pennsylvania: - Abramson Cancer Center — Philadelphia, Pennsylvania
- AHN Cancer Center — Pittsburgh, Pennsylvania
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Pennsylvania: - Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- West Penn Allegheny Health — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in Pennsylvania: - Alliance Cancer Specialists — Sellersville, Pennsylvania
Phase 3 Recruiting Industry
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in Pennsylvania: - AHN Cancer Institute - Allegheny General — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in Pennsylvania: - Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111) — Lancaster, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …
Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in Pennsylvania: - Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Pennsylvania: - WellSpan Medical Oncology and Hematology — Chambersburg, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
- Ephrata Cancer Center — Ephrata, Pennsylvania
- Adams Cancer Center — Gettysburg, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Pennsylvania: - UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
- UPMC Cancer Centers - Arnold Palmer Pavilion — Greensburg, Pennsylvania
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Pennsylvania: - Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- WellSpan York Cancer Center — York, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in th…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04665739
Sites in Pennsylvania: - Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Temple University Hospital — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each othe…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06162221
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania